NCT07370519Phase 2Recruiting
Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia
Safety and Efficacy of Lactobacillus Reuteri for Androgenetic Alopecia: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Shenzhen People's Hospital
- Participants (registry)
- 388
- Start
- January 2026
- Primary completion
- January 2027 (planned)
- Study completion
- June 2027 (planned)
- Last registry update
- April 2026
- Countries
- China
Conditions studied: Androgenetic Alopecia (AGA)
Interventions: Lactobacillus reuteri, Inactivated Lactobacillus reuteri, 5% Minoxidil, Normal Saline
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.